Citigroup
FENC icon

Citigroup’s Fennec Pharmaceuticals FENC Stock Holding History

Citigroup’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Buy
13,607
+12,214
+877% +$99.7K ﹤0.01% 4488
2026
Q1 		$8.31K Buy
1,393
+863
+163% +$6.66K ﹤0.01% 5110
2025
Q4 		$4.1K Sell
530
-281
-35% -$2.31K ﹤0.01% 5296
2025
Q3 		$7.57K Sell
811
-7,529
-90% -$65.2K ﹤0.01% 5096
2025
Q2 		$69K Sell
8,340
-8,858
-52% -$60.6K ﹤0.01% 4605
2025
Q1 		$110K Sell
17,198
-1,428
-8% -$9.17K ﹤0.01% 4552
2024
Q4 		$115K Buy
18,626
+1,392
+8% +$7.13K ﹤0.01% 4763
2024
Q3 		$85.6K Buy
17,234
+10,557
+158% +$61.1K ﹤0.01% 4835
2024
Q2 		$41.1K Buy
6,677
+1,986
+42% +$16.5K ﹤0.01% 4699
2024
Q1 		$52.3K Buy
4,691
+1,994
+74% +$20K ﹤0.01% 4597
2023
Q4 		$31K Buy
2,697
+2,587
+2,352% +$21.4K ﹤0.01% 4785
2023
Q3 		$823 Sell
110
-5,294
-98% -$43.1K ﹤0.01% 5124
2023
Q2 		$50.7K Sell
5,404
-13,186
-71% -$110K ﹤0.01% 4640
2023
Q1 		$151K Buy
18,590
+1,742
+10% +$16.2K ﹤0.01% 3878
2022
Q4 		$163K Buy
+16,848
New +$149K ﹤0.01% 3823
2021
Q2 		– Sell
-1,441
Closed -$9K – 6204
2021
Q1 		$9K Sell
1,441
-2,700
-65% -$20.3K ﹤0.01% 5687
2020
Q4 		$30K Buy
4,141
+3,113
+303% +$23.7K ﹤0.01% 6393
2020
Q3 		$6K Sell
1,028
-1,872
-65% -$13.2K ﹤0.01% 6894
2020
Q2 		$24K Buy
2,900
+1,782
+159% +$13.3K ﹤0.01% 6476
2020
Q1 		$7K Buy
+1,118
New +$7.29K ﹤0.01% 7158
2019
Q4 		– Sell
-1,308
Closed -$6K – 7706
2019
Q3 		$6K Sell
1,308
-465
-26% -$2.05K ﹤0.01% 7270
2019
Q2 		$8K Sell
1,773
-1,540
-46% -$6.52K ﹤0.01% 7363
2019
Q1 		$16K Buy
3,313
+267
+9% +$1.75K ﹤0.01% 7060
2018
Q4 		$19K Sell
3,046
-153
-5% -$1.07K ﹤0.01% 6897
2018
Q3 		$26K Buy
3,199
+1,571
+96% +$14.6K ﹤0.01% 6958
2018
Q2 		$17K Buy
+1,628
New +$19.3K ﹤0.01% 6993

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citigroup's FENC Position: Q2 2026 in Review

Citigroup increased its Fennec Pharmaceuticals (FENC) stake by 877% in Q2 2026, buying an estimated $99.7K and bringing the position to 13,607 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #4488.

Citigroup first reported a position in FENC in Q2 2018 and has held it in 26 quarters since. The position peaked at $163K in Q4 2022. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Citigroup held 13,607 shares of Fennec Pharmaceuticals worth $147K as of Q2 2026.
  • Citigroup bought 12,214 Fennec Pharmaceuticals shares in Q2 2026, an estimated $99.7K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4488 holding.
  • Citigroup first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 26 quarters since.
  • Citigroup's Fennec Pharmaceuticals position peaked at $163K in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.